The effect of different indomethacin formulations in young and elderly patients: a comparative controlled clinical trial.
In a double-blind, crossover trial a controlled-release multiple-units indomethacin formulation (50 mg twice daily) was compared with conventional capsules (25 mg twice daily with 50 mg in the evening) in 12 young and 18 elderly in-patients with rheumatoid arthritis. Earlier findings that younger patients preferred a slow-release formulation and the elderly a standard formulation could not be confirmed. As a whole, the duration of morning stiffness was reduced more (p = 0.02) with the controlled-release formulation than with the conventional formulation. During the treatment period (7 days), 4 patients reported side-effects from the conventional capsules, 3 from the controlled-release formulation, and 6 from both treatments; 53% of the patients preferred the controlled-release formulation, while 20% preferred the conventional capsule (p = 0.046).
Kaarela
K
K
Rheumatism Foundation Hospital, Heinola, Finland.
Lehtinen
K
K
Skinhøj
A
A
Andersen
F
F
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001294:Attitude to Health; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged
D003692:Delayed-Action Preparations; D007213:Indomethacin